骨保护素

Osteoprotegerin (OPG) is a secreted decoy receptor that inhibits osteoclastogenesis and thus plays a critical role in bone homeostasis.
骨保护素（OPG）是一种分泌型诱饵受体，它能够抑制破骨细胞生成，在维持骨骼稳态中发挥着关键作用。
High levels of osteoprotegerin have been associated with increased cardiovascular risk in several clinical studies.
多项临床研究发现，骨保护素水平升高与心血管疾病风险增加有关。
Osteoprotegerin expression is upregulated in patients with osteoporosis, as a compensatory mechanism to inhibit excessive bone resorption.
在骨质疏松症患者中，骨保护素表达上调作为一种补偿机制以抑制过度的骨吸收。
The administration of osteoprotegerin has shown promise in preclinical trials for the treatment of bone metastases.
骨保护素在治疗骨转移瘤的临床前试验中展现出良好的应用前景。
Genetic variations in the osteoprotegerin gene may influence an individual's susceptibility to developing osteoporosis.
骨保护素基因的遗传变异可能影响个体对骨质疏松症的易感性。
Serum osteoprotegerin levels can serve as a biomarker for evaluating the progression of renal dysfunction in chronic kidney disease.
血清骨保护素水平可以作为评估慢性肾病肾功能恶化的生物标志物。
Osteoprotegerin knockout mice display severe osteoporosis due to uncontrolled osteoclast activity.
骨保护素敲除小鼠由于无法控制的破骨细胞活性而表现出严重的骨质疏松症。
Recent research suggests that osteoprotegerin might also play a role in regulating energy metabolism and insulin resistance.
最近的研究表明，骨保护素可能还在调节能量代谢和胰岛素抵抗方面发挥作用。
In periodontal diseases, osteoprotegerin expression decreases, leading to enhanced alveolar bone loss.
在牙周病中，骨保护素表达降低，导致牙槽骨丧失加剧。
Anti-osteoprotegerin antibodies have been used experimentally to stimulate bone formation in cases of severe bone loss.
实验中已使用抗骨保护素抗体来刺激严重骨丢失情况下的骨形成。